All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
Equity

Cytos CB investors face default or conversion

Cytos Biotechnology, a Swiss company that has been struggling for years, has asked holders of its remaining convertible bonds to agree to a mandatory conversion to equity at a fraction of the original conversion price. Reaching a deal with bondholders is the company’s last chance to remain as a going concern.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree